Optimizing drug therapy in pediatric SCT: Focus on pharmacokinetics

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Bone Marrow Transplantation

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bmt.2014.235PMID 25347008PMCID PMC5996991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children.

  2014cited by this paper
• Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

  2014cited by this paper
• Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.

  2014cited by this paper
• Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization

  2013cited by this paper
• Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation.

  2013cited by this paper
• Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia.

  2013cited by this paper
• Variation in Prescribing Patterns and Therapeutic Drug Monitoring of Intravenous Busulfan in Pediatric Hematopoietic Cell Transplant Recipients

  2013cited by this paper
• Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil

  2013cited by this paper
• Intravenous versus oral busulfan-based conditioning for pediatric allogeneic hematopoietic cell transplantations: did the pendulum swing too far, too fast?

  2013cited by this paper
• Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors

  2013cited by this paper
• Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.

  2012cited by this paper
• Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.

  2012cited by this paper
• Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.

  2012cited by this paper
• Potential Contribution of Cytochrome P450 2B6 to Hepatic 4-Hydroxycyclophosphamide Formation In Vitro and In Vivo

  2012cited by this paper
• Nonmyeloablative Conditioning Regimen to Increase Engraftment of Gene-modified Hematopoietic Stem Cells in Young Rhesus Monkeys.

  2012cited by this paper
• Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.

  2012cited by this paper
• Population Pharmacokinetics of Unbound Mycophenolic Acid in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

  2012cited by this paper
• Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT

  2012cited by this paper
• National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.

  2011cited by this paper
• A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents

  2011cited by this paper
• Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring.

  2011cited by this paper
• Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.

  2011cited by this paper
• Differences in Clearance of Mycophenolic Acid Among Renal Transplant Recipients, Hematopoietic Stem Cell Transplant Recipients, and Patients With Autoimmune Disease

  2010cited by this paper
• Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia

  2010cited by this paper
• An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.

  2010cited by this paper
• Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.

  2010cited by this paper
• Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant

  2009cited by this paper
• A phase II study of Campath‐1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report

  2009cited by this paper
• Bioavailability of Mycophenolate Mofetil and Enteric‐Coated Mycophenolate Sodium Is Differentially Affected by Pantoprazole in Healthy Volunteers

  2009cited by this paper
• Population Pharmacokinetics of Cyclophosphamide and Metabolites in Children With Neuroblastoma: A Report From the Children's Oncology Group

  2009cited by this paper
• A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients

  2009cited by this paper
• Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation

  2009cited by this paper
• Busulfan in hematopoietic stem cell transplant setting

  2009cited by this paper
• A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients

  2009cited by this paper
• Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation

  2008cited by this paper
• Pharmacokinetics of alemtuzumab and the relevance in clinical practice

  2008cited by this paper
• Impact of expanded newborn screening--United States, 2006.

  2008cited by this paper
• Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT

  2008cited by this paper
• Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT)

  2008cited by this paper
• The Magnitude and Time Course of Changes in Mycophenolic Acid 12-Hour Predose Levels During Antibiotic Therapy in Mycophenolate Mofetil-Based Renal Transplantation

  2007cited by this paper
• Pharmacokinetics of Mycophenolate Mofetil in Hematopoietic Stem Cell Transplant Recipients

  2007cited by this paper
• Highly Variable Mycophenolate Mofetil Bioavailability Following Nonmyeloablative Hematopoietic Cell Transplantation

  2007cited by this paper
• Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.

  2007cited by this paper
• Prediction of Unbound Mycophenolic Acid Concentrations in Patients After Hematopoietic Cell Transplantation

  2007cited by this paper
• Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.

  2007cited by this paper
• Population Pharmacokinetic–Based Dosing of Intravenous Busulfan in Pediatric Patients

  2007cited by this paper
• High-unbound mycophenolic acid concentrations in an infant on peritoneal dialysis following hematopoietic cell transplant

  2007cited by this paper
• Optimization of allogeneic transplant conditioning: not the time for dogma

  2006cited by this paper
• Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector.

  2006cited by this paper
• Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes

  2006cited by this paper
• Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.

  2006cited by this paper
• Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.

  2006cited by this paper
• Hematopoietic stem-cell transplantation.

  2006cited by this paper
• Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.

  2006cited by this paper
• Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1

  2006cited by this paper
• Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation

  2005cited by this paper
• Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance‐Associated Protein 2

  2005cited by this paper
• High unbound mycophenolic acid concentrations in a hematopoietic cell transplantation patient with sepsis and renal and hepatic dysfunction.

  2005cited by this paper
• Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.

  2005cited by this paper
• Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity

  2005cited by this paper
• Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing.

  2005cited by this paper
• A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.

  2005cited by this paper
• Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicty.

  2005cited by this paper
• Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.

  2004cited by this paper
• Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite Carboxyethylphosphoramide mustard

  2004cited by this paper
• I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients

  2004cited by this paper
• Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.

  2003cited by this paper
• Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.

  2003cited by this paper
• Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.

  2003cited by this paper
• Developmental pharmacology--drug disposition, action, and therapy in infants and children.

  2003cited by this paper
• Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome.

  2003cited by this paper
• Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

  2002cited by this paper
• Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation

  2002cited by this paper
• Cellular and Clinical Pharmacology of Fludarabine

  2002cited by this paper
• A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome

  2001cited by this paper
• Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation

  2001cited by this paper
• Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation

  2001cited by this paper
• Pharmacokinetics of CAMPATH-1H in BMT patients.

  2001cited by this paper
• Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism

  2001cited by this paper
• Plasma concentration monitoring of busulfan: does it improve clinical outcome?

  2000cited by this paper
• Plasma Concentration Monitoring of Busulfan

  2000cited by this paper
• An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease

  2000cited by this paper
• Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia

  2000cited by this paper
• Up-regulation of glutathione S-transferase activity in enterocytes of young children.

  1999cited by this paper
• Aging and the Immune System

  1998cited by this paper
• Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

  1998cited by this paper
• Encyclopedia of immunology

  1998cited by this paper
• Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.

  1997cited by this paper
• Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics.

  1995cited by this paper
• Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy.

  1995cited by this paper
• Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.

  1992cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.

  1987cited by this paper
• Clinical Pharmacokinetics of Cyclophosphamide

  1979cited by this paper

• Body Surface Area-Based Dosing of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Prospective Population Pharmacokinetic Study

  2023cites this paper
• Knowledge, attitudes and practices of Egyptian healthcare professionals toward therapeutic drug monitoring service as a principal component of personalized medicine.

  2022cites this paper
• Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia

  2022cites this paper
• Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

  2021cites this paper
• A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation

  2020cites this paper
• Stem Cell Transplantation in Pediatrics

  2020cites this paper
• Pharmacotherapy in Pediatric Hematopoietic Cell Transplantation.

  2019cites this paper
• Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients

  2018cites this paper
• Individualized Dosing of Serotherapy in Allogeneic Hematopoietic Cell Transplantation: Scope and Intent of the Investigations

  2017cites this paper
• Optimal conditioning regimens for cord blood transplantation: advances and challenges

  2017cites this paper
• Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients

  2017cites this paper
• Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect

  2016cites this paper
• Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: The need to look beyond post‐transplantation cyclophosphamide in younger children

  2016cites this paper
• A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.

  2016cites this paper
• Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II

  2016cites this paper
• Improving preclinical cancer models: lessons from human and canine clinical trials of metronomic chemotherapy

  2016cites this paper